This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
Close
Close
Close
Close
Close
Close

Theramex News

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Get in touch

Close

Careers

14 April 2022

Theramex UK Stock Update

Theramex is pleased to advise that the full range of Evorel® (estradiol or estradiol/norethisterone) patches are currently in stock across the UK and we do not expect any stock issues based on current levels of demand.

Thanks to the incredible work of healthcare professionals and menopause activists, more women are informed about their menopause and the options available to them, and therefore there has been a significantly greater level of demand over the past year for HRT. Most women in the UK now use transdermal HRT patches, as a result we have increased capacity at all stages of production to meet this demand and ensure people can continue to access our products. 

We are working closely with Government and relevant partners to ensure the continued supply of our products and anticipate any future increases in demand. While HRT stock issues continue in other sectors of the market, we recommend people work with their clinician to understand availability of various products, suitable alternatives and appropriate prescription intervals to enable companies to best manage supply.

17 June 2022

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids

Read more

28 March 2022

A consortium of Carlyle and PAI Partners to acquire Theramex from CVC Funds

Read more